NRG BN010

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Open

A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

NCT#04729959

BN010 is reopened to accrual to the safety run-in, dose level 2, effective September 26, 2022.

BN010, safety run in, dose level 1, is closed to accrual, effective June 29, 2022.